ZNF217 and breast cancer: Although ZNF217 has not been shown to bind to AR (http://www.immunobase.org), it does bind to the estrogen receptor (ER) [107, 108] and is appreciated to be a biomarker of ERα-positive breast cancers [109], suggesting that it may play a regulatory role in conjunction with nuclear receptors.